01 8Loxonin
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 225
2019 Revenue in Millions : 265
Growth (%) : -15
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 192
2020 Revenue in Millions : 224
Growth (%) : -8
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2022 Revenue in Millions : 148
2021 Revenue in Millions : 192
Growth (%) : -23
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2023 Revenue in Millions : 111
2022 Revenue in Millions : 148
Growth (%) : -16
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2024 Revenue in Millions : 89
2023 Revenue in Millions : 111
Growth (%) : -19
Main Therapeutic Indication : Anti-inflammatory
Currency : USD
2017 Revenue in Millions : 376
2016 Revenue in Millions : 356
Growth (%) : 6
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2018 Revenue in Millions : 286
2017 Revenue in Millions : 353
Growth (%) : -19%
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 269
2018 Revenue in Millions : 296
Growth (%) : -9
